Back to School: How biopharma can reboot drug development. Access exclusive analysis here
NEXM was up $1.85 (71%) to $4.45 on 5.5 million shares on Thursday on news that
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury